Aravive, Inc.
NASDAQ: ARAV0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Fredric N. Eshelman
- Employees
- 23
- Headquarters
- Houston, United States
- IPO year
- 2014
- Market cap
- $2.9M
- Website
- https://aravive.com
Loading ARAV…
Loading profile data…Frequently asked questions about ARAV
What does Aravive, Inc. (ARAV) do?
Aravive, Inc. is a clinical-stage biopharmaceutical company, based in Houston, Texas, dedicated to discovering and developing innovative treatments for life-threatening illnesses such as cancer and fibrosis. The company's primary therapeutic candidate, batiraxcept, is an ultrahigh-affinity decoy protein engineered to disrupt the GAS6-AXL signali...
Where does ARAV trade?
Aravive, Inc. (ARAV) trades on the NASDAQ Global Select.
What sector is ARAV in?
Aravive, Inc. (ARAV) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Aravive, Inc.?
Fredric N. Eshelman is the chief executive officer of Aravive, Inc. (ARAV).
Where is Aravive, Inc. headquartered?
Aravive, Inc. is headquartered in United States.
Does ARAV pay a dividend?
Aravive, Inc. (ARAV) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ARAV go public?
Aravive, Inc. (ARAV) completed its initial public offering in 2014.